The meta-analysis by De La Cruz-Vargas et al. notes that IL-6 inhibitors are being evaluated clinically, but as of yet, there is no conclusive evidence that they improve outcomes in breast cancer [7]. The gene discussed is IL6; the disease is breast cancer.